Oncopeptides

Oncopeptides is a commercial-stage biotech focused on developing targeted peptide-drug conjugates for oncology. Its core achievement is the full European marketing authorization of Pepaxti (melphalan flufenamide) for relapsed/refractory multiple myeloma, which is now generating revenue through direct commercialization in key European markets. The company's strategy is to drive adoption of Pepaxti, expand its label, and leverage its proprietary PDC and SPiKE platforms to advance new candidates, including an early-stage glioblastoma program with fast-track designation. Oncopeptides is publicly traded on Nasdaq Stockholm (ONCO).

Proprietary Peptide-Drug Conjugate (PDC) platform that uses tumor-targeting peptides to deliver potent alkylating agents, and a preclinical Small Polypeptide-based Killer Engagers (SPiKE) bispecific platform.

Pepaxti competes in a crowded multiple myeloma market against novel modalities like bispecific antibodies and CAR-Ts, differentiating via its PDC mechanism and administration profile. In glioblastoma, competition is from standard chemo/radiotherapy, representing a high-unmet-need but challenging development environment.